Menu
Search
Home > Courses > HIV Antiretroviral Therapy 2017: Clinical Controversies in When and What to Start

HIV Antiretroviral Therapy 2017: Clinical Controversies in When and What to Start

HIV Antiretroviral Therapy 2017: Clinical Controversies in When and What to Start
Play
Sorry, this learning module is not available for mobile devices.
Original Release Date: 2/7/2017
Review Date: 4/17/2017
Presenter
  • Rajesh T. Gandhi, MD
    Director of HIV Clinical Services and Education
    Massachusetts General Hospital
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
  1. Be able to discuss the optimal timing of initiation of antiretroviral therapy in HIV-infected patients.
  2. Be able to summarize the latest recommendations for first-line antiretroviral regimens in HIV-infected patients.
  3. Be able to evaluate how to individualize the choice of an antiretroviral regimen based on a patient’s specific comorbidities and conditions.
Presenter Bio
Rajesh Gandhi, MD
Rajesh T. Gandhi, MD, is a Professor of Medicine at Harvard Medical School, and the Director of HIV Clinical Services and Education at Massachusetts General Hospital (MGH). Dr. Gandhi is the site leader of the MGH AIDS Clinical Research Site in the Harvard/Miriam AIDS Clinical Trials Unit and chair of the AIDS Clinical Trials Group (ACTG) HIV-1 Reservoirs and Eradication Transformative Science Group. He is also the Director of the Harvard University Center for AIDS Research Clinical Core (CFAR). Dr. Gandhi is the editor of Partners ID Images, an educational infectious diseases website, and organizer of the HIV Online Provider Education (HOPE) program, an internet-based educational conference series for physicians and nurses caring for HIV-infected patients in resource-limited settings. He is also a Deputy Editor of NEJM Journal Watch Infectious Diseases and NEJM Journal Watch HIV/AIDS. He is a scientific member of the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, and the International Antiviral Society-USA Panel on Antiretroviral Drugs for Treatment and Prevention of HIV in Adults.
Continuing Education Credit (The CE accreditation for this course has expired - this section is only for your information)

This CME activity was approved for AMA PRA Category 1 Credit™ on February 7, 2017 and will terminate February 6, 2020.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
  • You must achieve at least 70% correct to receive your CME certificate.
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement 

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.  

  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
  • Dr. Rajesh Gandhi (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Educational grants from Gilead, Merck, and ViiV.  Dr. Gandhi submitted his slides in advance for adequate peer review, and will support his presentation and clinical recommendations with the best available evidence from the medical literature.

Financial Support

This meeting of the Physicians' Research Network (PRN) and enduring material were funded in part by educational grants from: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and ViiV Healthcare.

Details:

This online video and post-activity evaluation are one hour in length. 

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
PRN Learning Modules